Collegium Pharmaceutical, Inc. (COLL) 股票分析

公司概述

Collegium Pharmaceutical, Inc. operates as a specialty pharmaceutical company focused on the development and commercialization of medicines specifically designed for pain management. The firm functions within the Healthcare sector, more precisely categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a concentration on niche therapeutic areas rather than broad-market products. The company demonstrates a significant operational scale, supported by a workforce of 423 employees and a total market capitalization of $1.14 billion. Its annual revenue stands at $780.57 million, a figure that suggests the company holds a substantial position within its specific niche, generating nearly one billion dollars in economic activity annually despite its mid-cap classification. These valuation and revenue metrics collectively indicate that Collegium has established a resilient market presence capable of sustaining operations and investing in its specialized portfolio, including assets like Jornay PM.

财务健康

The company reported revenue of $780.57 million over the trailing twelve months, with net income reaching $62.87 million and EBITDA totaling $419.16 million. The substantial gap between the $780.57 million in revenue and the $62.87 million in net income reveals a cost structure where approximately 92% of revenue is consumed by costs of goods sold, operating expenses, and taxes before arriving at the bottom line. Despite this large operating expense burden, the company generated $321.54 million in free cash flow, a robust figure that provides significant financial flexibility for strategic initiatives or debt servicing without relying on external financing. The gross margin of 88.5% indicates high pricing power and low direct production costs relative to sales, while the operating margin of 30.0% reflects efficient management of overheads relative to revenue. However, the profit margin of 8.1% shows that non-operating expenses or tax liabilities further compress the final return to shareholders. On the liability side, the company holds $386.68 million in cash against $936.43 million in debt, resulting in a debt-to-equity ratio of 310.41 which characterizes a highly leveraged balance sheet. Nevertheless, the current ratio of 1.57 indicates that short-term assets exceed short-term liabilities, suggesting adequate liquidity to meet obligations as they fall due. Additionally, the return on equity of 23.7% and return on assets of 7.3% demonstrate that management is effectively utilizing shareholder capital and total assets to generate returns, particularly notable given the high leverage levels.

估值评估

Collegium Pharmaceutical trades with a trailing twelve-month P/E ratio of 20.38 and a forward P/E ratio of 5.52. The stark disparity between the trailing and forward P/E multiples implies that the market expects a significant contraction in earnings or a re-rating of the stock price that would bring current valuations in line with future projections. The price-to-book ratio stands at 3.71, indicating that the market values the company at a substantial premium of roughly 271% over its tangible book value. Alternative valuation metrics such as the price-to-sales ratio of 1.46 and the EV/EBITDA of 3.98 provide further context, suggesting the stock is priced modestly relative to sales but considering the high debt load, the enterprise value multiple remains compressed. The stock's recent trading range is bounded by a 52-week high of $50.79 and a 52-week low of $23.23. Without a specific current price provided in the source data, the precise percentage distance from the high or low cannot be calculated, but the wide range of $27.56 suggests high volatility within the year. The beta value of 0.77 indicates that the stock's price volatility is roughly 23% lower than the broader market, suggesting it may act as a defensive holding during periods of market turbulence relative to larger market-cap peers.

Growth & Income

Revenue growth over the past year stands at 12.9%, while earnings growth has accelerated to 31.5%. This divergence indicates that earnings are growing at a rate nearly 2.5 times faster than revenue, which implies significant operational leverage or cost efficiencies that are magnifying profit growth relative to top-line expansion. As the dividend yield is listed as N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders. This non-dividend status means the company retains all earnings, effectively reinvesting them into growth initiatives, research, or debt reduction rather than providing passive income to investors. The overall growth and income profile is characterized by double-digit revenue expansion and triple-digit earnings growth rates, coupled with a zero-dividend strategy that prioritizes capital allocation for long-term business development over immediate income distribution.